Sector News

Roche CEO attacks Britain’s ‘stupid’ cancer drug system

September 9, 2015
Life sciences

(Reuters) – Roche Chief Executive Severin Schwan criticized Britain’s health system on Tuesday after two of the company’s cancer drugs were dropped from use, calling it a “stupid” way to control costs that could jeopardize research in the country.

He also criticized India, an emerging economic powerhouse, for not doing more to increase its spending on healthcare.

Roche, as the world’s biggest maker of cancer drugs, has had frequent run-ins with Britain over its system for curbing use of medicines that are not considered cost effective.

The latest clash came on Friday, when a government fund that helps patients receive cancer drugs not routinely paid for by the National Health Service said it would no longer pay for a number of medicines.

The Swiss drugmaker’s Avastin for certain cancers and Kadcyla for breast cancer were among products “de-listed” by the Cancer Drugs Fund (CDF).

Schwan said the decision failed to recognize the value such medicines offered society by keeping patients out of hospital and allowing them to remain productively employed.

“It’s stupid from a cost point of view not to look at the overall cost of healthcare,” he told a media briefing.

“This is really sad for patients and I have no understanding for this decision whatsoever … there is a fundamental flaw in how the UK operates when it comes to pricing for medicine.”

The CDF, defending the cuts last week, said it had to make difficult choices but that it was its duty to ensure maximum value for money.

Schwan said there would be also knock-on effects for research in Britain, since if drugs like Avastin were not available as standard then Roche would not be able to do certain clinical trials in the country.

“Eventually, this will hurt us on the research side in the UK. This is just a bad decision, not only for patients but also for society as a whole,” Schwan said.

Britain’s pharmaceuticals industry also complained this week about the country’s slow adoption of new medicines in clinical practice, although drug companies also face hurdles in getting the latest drugs prescribed in other European markets.

The Roche boss had harsh words for India, too, saying the country was not spending enough as a percentage of its gross domestic product on healthcare, estimating it at only about 1 percent to 2 percent.

He said that salvos targeting drug companies over the high cost of medicines in developing countries were distractions from this more important issue.

“You have a real lack of healthcare infrastructure which doesn’t even enable generic companies to bring medicines to the Indian population,” Schwan said.

By John Miller (Additional reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).